Universal Autofoundry manufactures and machines iron castings, such as suspension brackets and engine components, primarily for commercial vehicle and tractor manufacturers in India and abroad.
The company lacks a durable moat, as evidenced by net margins below 2% and a recent swing into losses despite stable revenue. While it has long-term OEM relationships, the business is a price-taking commodity converter vulnerable to raw material spikes and intense competition from a former promoter's rival firm.
Capital has been heavily directed toward capacity expansion (Unit 3) and a large solar power project (43 crore total investment) to lower energy costs. However, these investments have yet to translate into improved returns, with EPS declining significantly and ROCE remaining mediocre.
The company's aggressive capacity expansion and solar investments failed to offset the structural disadvantage of being a price-taking commodity converter. As the former promoter's rival firm aggressively poached key OEM accounts using insider knowledge, margins—already razor-thin—collapsed into permanent losses. The heavy debt load incurred for Unit 3 became a noose as interest coverage remained negative, eventually leading to a liquidity crunch and a distressed equity raise that diluted shareholders into a permanent loss of capital.
RichFakir rates Universal Autofoundry Ltd's business quality as poor — 22/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Universal Autofoundry Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Universal Autofoundry Ltd is: Not rated. A poor business at an expensive price — it does not make our shortlist right now.
RichFakir's educational estimate of Universal Autofoundry Ltd's fair value is about ₹21 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →